First-line afatinib significantly prolonged progression-free survival (PFS) versus platinum-based chemotherapy in two phase III trials in patients with EGFR mutation-positive NSCLC, and is approved for the treatment of these patients in several countries, including the USA and the European Union [4, 5]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.